Search Results - "Vining D"

Migration between the core and the periphery.

Authors: Vining, D. R., Jr

Source: Scientific American; Dec 1982, Vol. 247, p44-53, 10p

Dihydroxynaphthaldehydes.

Authors: Morgan, G. T. Vining, D. C.

Source: Journal of the Chemical Society; February 1921, Vol. 119, p177-187, 11p

Action of methyl sulphate on diphenylamine and on methyldiphenylamine.

Authors: Gibson, C. S. Vining, D. C.

Source: Journal of the Chemical Society; April 1923, Vol. 123, p831-841, 11p

Dinaphtha-1:7:1':7'-diquinone.

Authors: Morgan, G. T. Vining, D. C.

Source: Journal of the Chemical Society; November 1921, Vol. 119, p1707-1714, 8p

Dimorphism of diphenylarsenious chloride.

Authors: Gibson, C. S. Vining, D. C.

Source: Journal of the Chemical Society; April 1924, Vol. 125, p909-911, 3p

Compounds of arsenious chloride and pyridine.

Authors: Gibson, C. S. Johnson, J. D. A. Vining, D. C.

Source: Journal of the Chemical Society; July 1930, pp1710-p1711, 2p

The effect of sulindac on growth differentiation factor 15 and 13,14-dihydro-15-keto prostaglandin A2 in nipple aspirate fluid.

Authors: Thompson, P. A. Vining, D. R. May, M. et al.

Source: BMC Proceedings. 2009 Supplement 5, Vol. 3, p1-2. 2p.

Increasing returns to city size in the face of an impending decline in the sizes of large cities: Which is the bogus fact?

Authors: Kontuly, T. Vining, D. R., Jr.

Source: Environment & Planning. Jan1977, Vol. 9 Issue 1, p59. 0p.

Recent migration patterns in the developed world: a clarification ofsome differences between our and IIASA's findings

Authors: Pallone, R. Plane, D. Vining, D.

Source: Environment & Planning. Feb1981, Vol. 13 Issue 2, p243. 0p.

638P Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center.

Authors: Tsimberidou, A.M. Fu, S. Hong, D.S. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS506-S507. 2p.

449PD - Precision medicine: Preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study.

Authors: Tsimberidou, A.M. Hong, D.S. Fu, S. et al.

Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv165-v165. 1p.

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.

Authors: Hinchcliff EM Knisely A Adjei N et al.

Source: Cancer [Cancer] 2024 Apr 01; Vol. 130 (7), pp. 1061-1071. Date of Electronic Publication: 2023 Nov 27.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy.

Authors: Dai Y Knisely A Yano M et al.

Source: Nature [Nature] 2025 Sep; Vol. 645 (8082), pp. E10.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE; In Process

PPP2R1A mutations portend improved survival after cancer immunotherapy.

Authors: Dai Y Knisely A Yano M et al.

Source: Nature [Nature] 2025 Aug; Vol. 644 (8076), pp. 537-546. Date of Electronic Publication: 2025 Jul 02.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.

Authors: Morris VK Jazaeri A Westin SN et al.

Source: The oncologist [Oncologist] 2023 Jul 05; Vol. 28 (7), pp. 618-623.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.

Authors: Amaria R Knisely A Vining D et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Feb 02; Vol. 12 (2). Date of Electronic Publication: 2024 Feb 02.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.

Authors: Naqvi MF Vo HH Vining D et al.

Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2021 Mar 24; Vol. 13, pp. 17588359211001538. Date of Electronic Publication: 2021 Mar 24 (Print Publication: 2021).

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Authors: Tsimberidou AM Guenther K Andersson BS et al.

Source: Cancer immunology research [Cancer Immunol Res] 2023 Jul 05; Vol. 11 (7), pp. 925-945.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center.

Authors: Vo HH Cartwright C Song IW et al.

Source: Cancers [Cancers (Basel)] 2022 Mar 04; Vol. 14 (5). Date of Electronic Publication: 2022 Mar 04.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.

Authors: Tsimberidou AM Beer PA Cartwright CA et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 01; Vol. 27 (13), pp. 3584-3594. Date of Electronic Publication: 2021 May 04.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE